Liminatus Pharma, Inc. filed a Form D with the Securities and Exchange Commission on 2026-06-18.
Liminatus Pharma, Inc. filed a Form D notice of an exempt securities offering with the SEC on June 18, 2026. The filing reports $1.86M sold. Its industry group is Pharmaceuticals. It names Chris Kim (Executive Officer, Director), Scott Dam (Executive Officer), Byong Yoo (Executive Officer) (SEC Form D, June 18, 2026).
Who owns Liminatus Pharma, Inc.?
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Liminatus Pharma, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-06-18 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Liminatus Pharma, Inc.
Free to see. No signup.
More on the people and the money behind Liminatus Pharma, Inc., from the filings we hold.
Pharmaceuticals raises by companies based in California, filed within 90 days of this one, largest first.
Get an email when Liminatus Pharma, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Liminatus Pharma, Inc. raises, hires or launches. No email unless you switch it on.
Watch Liminatus Pharma, Inc. →Get the full cited report on Liminatus Pharma, Inc.
What the filing shows about Liminatus Pharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Liminatus Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Liminatus Pharma, Inc.'s address as 2251 Stern Goodman Street, Suite E, Fullerton, CA 92833.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Liminatus Pharma, Inc. is a registered filer with the SEC (CIK 1971387) and has filed since 2026-06-18. 1 filing is on record, the latest on 2026-06-18.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Liminatus Pharma, Inc.'s Form D of 2026-06-18 names Chris Kim, Scott Dam, Byong Yoo and 5 more as its officers, directors or promoters.
Its new offerings report $1.86M sold across 1 offering, as its own filings state.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $1.86M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Liminatus Pharma
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Chris Kim is named as Executive Officer and Director on the Form D that Liminatus Pharma, Inc. filed with the SEC on 18 June 2026, one of 8 people that filing names.
Scott Dam is named as Executive Officer on the Form D that Liminatus Pharma, Inc. filed with the SEC on 18 June 2026, one of 8 people that filing names.
Byong Yoo is named as Executive Officer on the Form D that Liminatus Pharma, Inc. filed with the SEC on 18 June 2026, one of 8 people that filing names.
Sang-jin Lee is named as Executive Officer on the Form D that Liminatus Pharma, Inc. filed with the SEC on 18 June 2026, one of 8 people that filing names.
Beom Choi is named as Executive Officer on the Form D that Liminatus Pharma, Inc. filed with the SEC on 18 June 2026, one of 8 people that filing names.
Eun Lee is named as Director on the Form D that Liminatus Pharma, Inc. filed with the SEC on 18 June 2026, one of 8 people that filing names.
Nicholas Fernandez is named as Director on the Form D that Liminatus Pharma, Inc. filed with the SEC on 18 June 2026, one of 8 people that filing names.
Ji Baek is named as Director on the Form D that Liminatus Pharma, Inc. filed with the SEC on 18 June 2026, one of 8 people that filing names.
8 people named on the filing — 5 holding an executive role and 3 as directors only.
Named as of the 2026-06-18 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Liminatus Pharma, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Liminatus Pharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Liminatus Pharma, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Liminatus Pharma, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Liminatus Pharma, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (liminatuspharma.com).
Each opens in a new tab, filled in for Liminatus Pharma, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/liminatus-pharma-inc-form-d-26000001